Clinical Trials Logo

Clinical Trial Summary

Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.


Clinical Trial Description

Preliminary research indicated that impaired antioxidant defense and increased lipid peroxidation is associated with brain changes during the onset of psychosis. Oxidative cell injury may contribute to poor outcomes in some patients. This study will define the extent and nature of oxidative cell injury that is associated with psychopathology at the onset of psychosis.

Participants in this study will be patients at the D. D. Eisenhower Army Medical Center who are experiencing a psychotic episode for the first time. Patients will be compared with 40 healthy volunteers (control group) matched with patients for age, gender, education, ethnic background, and occupational status. Patients and volunteers will have blood tests to determine the level of oxidative cell injury. Tests will be performed at onset of psychosis, and after 6 and 12 weeks of neuroleptic drug treatment. Medical histories and MRI scans will be used to examine the relationship of the laboratory tests to the clinical presentation. ;


Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal


Related Conditions & MeSH terms


NCT number NCT00070889
Study type Observational
Source National Center for Complementary and Integrative Health (NCCIH)
Contact
Status Completed
Phase N/A
Start date September 1999
Completion date August 2004

See also
  Status Clinical Trial Phase
Completed NCT01196858 - Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland N/A
Completed NCT00159120 - Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia Phase 4
Completed NCT00159133 - Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia Phase 4
Completed NCT00087542 - Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug Phase 2
Completed NCT00095810 - Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease Phase 4
Recruiting NCT00752960 - DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics N/A
Completed NCT00469365 - Pharmacy Interventions to Improve Chronic Disease Medication Refill Phase 3
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00204061 - Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis Phase 4
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Active, not recruiting NCT00260273 - Access, Detection and Psychological Treatments N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT03609515 - Patient-controlled Admissions in Inpatient Mental Health Services N/A